Kornimate/medical-research-clean huggingface dataset:
efficacy of cpap therapy on pulmonary function test in patients with copd-osa overlap syndrome

Conditions: COPD; OSA; Lung Function Decreased

Summary: to evaluate efficacy of cpap therapy on pulmonary function test in patients with copd-osa overlap syndrome

to evaluate efficacy of cpap therapy on pulmonary function test in patients with copd-osa overlap syndrome by 6 minute walking distance and oxygen consumption.

Eligibility criteria:
inclusion criteria: * diagnosis with copd by gold guideline criteria (post bronchodilator fev1/fvc \< 0.7 or \< lln) with post bronchodilator fev1 = 30-80% * diagnosis with obstructive sleep apnea with ahi \> 15 event/hr. (moderate osa or more) * age between 40-80 years * stable disease prior to inclusion. exclusion criteria: * diagnosis with \> 50% of central sleep apnea event * history of copd exacerbation during the past 8 week prior to inclusion. * subjects who cannot perform spirometry test or walking test * subjects with recording history of chronic heart failure, significant arrhythmias, acute myocardial infarction, moderate to severe mitral or aortic valve disease and pulmonary hypertension. * subjects with interstitial lung disease. * subjects with neuromuscular disease. * subjects with morbid obesity (bmi \>/=35) * subjects with chronic respiratory infection. * subjects with chronic co2 retension (paco2 \>/= 45 from arterial blood gas analysis) or transcutaneous co2 during sleep test \>/= 45 or serum bicarbonate level \> 27 * subjects with acute or active respiratory infecton during 2 week prior to inclusion.

Keywords: copd-osa overlap syndrome pulmonary function test
premenstrual dysphoric disorder:knowledge,attitude and practice among egyptian females

Conditions: Premenstrual Dysphoric Disorder

Summary: it is a cross-sectional study conducted in female patients attending outpatient clinc in our university hospital to assess their awareness regarding the symptoms of premenstrual dysphoric disorders.

this study will be conducted on females in the reproductive age attending the gynecological outpatient clinic to assess the prevalence of premenstrual dysphoric disorder(eeipmdd) and their awareness regarding the symptoms of pmdd and the impact of these symptoms on their quality of life using questionnaire including ( knowledge , attitude and practice) of those egyptian females.

Eligibility criteria:
inclusion criteria: females in reproductive age history of regular menstruation exclusion criteria: history of any psychological disorders history of chemotherapy in last 6 months
genetic variants and non-genetic variables and postoperative nausea and vomiting

Conditions: Anesthesia; Analgesia; Surgical Procedure, Operative

Summary: prospective observational study to analyse the association of non-genetic variables as well as genetic variants of candidate genes with the incidence of postoperative nausea and vomiting (ponv).

background surgery and anesthesia are related to unwanted adverse events, side effects and postoperative discomfort. postoperative nausea and vomiting are frequent and the question arises which patient is at specific risk for these sequelae. some predisposing factors for ponv are well described, e.g. female sex, non-smoking status and postoperative opioids. some drugs used for anesthesia as well as surgery related variables might induce ponv. in this prospective association study patient related variables, surgical and anesthesia related variables as well as genetic variants of several candidate genes will be investigated in a well-described patient cohort presenting for scheduled surgery. objective the aim of this study is to investigate a possible association of non-genetic variables and genetic variants with ponv. methods prospective association study performed in patients recovering form elective surgery and anesthesia.

Eligibility criteria:
inclusion criteria: * 18 years and older * written informed consent * elective surgery exclusion criteria * no written informed consent * cognitive impairment

Keywords: genetic association study postoperative nausea and vomiting patient reported outcome antiemetics
comparative analysis of serum lipid profiles in patients with and without gallstones

Conditions: Gallstone; Dyslipidemias

Summary: gallbladder disease is one of the most common diseases of the gastrointestinal tract. various studies have shown an association between gallstones and an alteration in the serum lipids. the objective of this study will be to compare serum lipid profile of gallstone patients with the controls.

this prospective cross-sectional study will be conducted in the surgical department of the services institute of medical sciences. a total of 50 patients will beincluded in the study after screening through the inclusion criteria. a control group of 50 inpatients with no personal or family history of gallstones will be also recruited for comparison. results will be expressed as mean with standard deviation. students t- test will be used to compare the data between the patients and the control groups (p\<0.05 will be considered statistically significant). spss software, version 20 will be used for statistical analysis.

Eligibility criteria:
inclusion criteria: * male or female patients with the gall stone disease * age from 20 to 70 years * gallstones were diagnosed through the ultrasound exclusion criteria: * patients with acalculous gallbladder disease on ultrasound, * patients with terminal ileal resection, * patients with hemolytic diseases (hereditary spherocytosis, sickle cell anemia on history and cbc film), * patients with liver cirrhosis (on abdominal ultrasound) and * patients on antihyperlipidemic drugs
optimisation of ect based on asti vs narcotrend

Conditions: Major Depressive Disorder

Summary: the electro-convulsion-therapy (ect) is a well accepted treatment option in severe depression. the quality of ect is evaluated basing on minimal seizure duration (\>15sec), the sympathic response and the postictal eeg-suppression. - page 1 of 3 - for the treatment general anaesthesia is needed. on the other hand anaesthesia strongly influences the quality of the seizure. standard treatment is to use anaesthesia to intervention time (asti) of 1 to 2 minutes for ideal timing of the electric stimulation. the aim of the study is to assess if timing of electric stimulation aiming for ar an anaesthesia depth of narcotrend values 41-64 may provide better convulsion quality than standard approach of using asti 1-2 minutes.

the electro-convulsion-therapy (ect) is a well accepted treatment option in severe depression. the quality of ect is evaluated basing on minimal seizure duration (\>15sec), the sympathic response and the postictal eeg-suppression. - page 1 of 3 - for the treatment general anaesthesia is needed. on the other hand anaesthesia strongly influences the quality of the seizure. standard treatment is to use anaesthesia to intervention time (asti) of 1 to 2 minutes for ideal timing of the electric stimulation. the aim of the study is to assess if timing of electric stimulation aiming for ar an anaesthesia depth of narcotrend values 41-64 may provide better convulsion quality than standard approach of using asti 1-2 minutes.

Eligibility criteria:
inclusion criteria: * asa 1-3 * age: 18 -90 years * signed informed consent * severe depressive disorder exclusion criteria: * asa \>3 * age \ 90 * denial of the patient * impossibility to fix narcotrend electrodes * patients unable to consent * pregnancy
optical surface guidance for external radiotherapy of head and neck cancer

Conditions: Otorhinolaryngeal Cancer

Summary: the goal of this clinical trial is to test the use of surface repositioning alone, without a restraint mask, during radiotherapy sessions for patients with head and neck cancer.

in radiotherapy treatments for head and neck cancer, the use of a mask is recommended for patient immobilization. the mask completely covers the head and shoulders, ensuring reproducible positioning at every session. however, using a mask can be oppressive and anxiety-provoking for patients. at the same time, technological developments have led us to use optical surface camera systems to position and monitor patients in the treatment room. in this way, if a movement exceeding the threshold is detected during a session, the treatment is automatically interrupted. however, despite the use of the mask, movements are still possible underneath, and are not detected by the surface cameras. the study's hypothesis is that the use of surface repositioning alone could guarantee reproducible treatment, as in combination with a thermoformed mask. in addition, eliminating the mask would mean greater comfort and improved quality of life for patients.

Eligibility criteria:
inclusion criteria: * patients over 18 years of age * patients undergoing palliative or curative treatment for oro-rhino-laryngeal cancer * patients with an indication for radiotherapy treatment, with or without complementary treatment (chemotherapy, immunotherapy), with a number of sessions between 10 and 35 * patients who have dated and signed an informed consent form exclusion criteria: * patients with uncontrollable movements * patients under psychiatric care * patients who do not understand or read french * patients participating in an interventional study testing another medical intervention * patients under guardianship, curatorship, safeguard of justice or deprived of liberty * pregnant or breast-feeding women * patients without social security coverage

Keywords: radiotherapy optical surface guidance
measuring head control change with 2d video analysis after utilization of headpod in children with poor head control

Conditions: To Determine Efficacy of the Headpod; Cerebral Palsy

Summary: inclusion criteria: children ages 2 to 14 years with poor head control and non progressive diagnoses. exclusion criteria: significant change of status i.e. prolonged hospitalization, surgery; inability to tolerate using headpod. requires use of headpod 3x per day for minimum of 15 minutes each time over a 6 month period. log must be kept documenting usage of the headpod. video will be taken to document changes.

requires usage of the headpod 3x per day for a minimum of 15 minutes each time. usage required for 6 month period. log must be kept documenting usage of the headpod. video will be taken on initial trial use, 1 week post trial use, at 3 months post utilization of the headpod and at 6 months post utilization of the headpod.

Eligibility criteria:
inclusion criteria: * non progressive diagnoses with poor head control exclusion criteria: * recent prolonged hospitalization; surgery, inability to tolerate wearing the headpod
efficacy of pain neurophysiology education in combination with psychologic inoculation in chronic whiplash

Conditions: Pain, Chronic; Whiplash Injury

Summary: with the present study the investigators wish to examine if reconceptualisation of pain, by educating chronic whiplash-associated disorders (cwad) patients on the neurophysiology of pain, in combination with psychologic innoculation is able to influence maladaptive (pain) cognitions, pain (inhibition) and movement performance, and reduce symptoms.

results from a previous pilot study conducted by the same investigators suggest that intensive pain neurophysiology education (pne) is able to increase pain thresholds and improve pain behavior and pain-free movement performance in patients with cwad. however these results have not been confirmed in a randomized controlled trial. in addition, it has been emphasized that pne is not a standalone treatment and that future research should examine pne in combination with other treatment modalities. another treatment modality that challenges people's beliefs and barriers is psychological inoculation (pi). however, it has not yet been examined if pi could be a useful component in the rehabilitation of chronic pain patients.

Eligibility criteria:
inclusion criteria: * wad grades i to ii according to the quebec task force criteria * with chronic pain as result of a whiplash injury * 18-65 years of age and with dutch as their native language will be able to participate exclusion criteria: * other comorbidities or health issues that could explain the pain complaints * \ 65 years * pregnant
erlotinib as first-line treatment of advanced non-small cell lung cancer (nsclc) for patients unfit for chemotherapy

Conditions: Non Small Cell Lung Cancer

Summary: a phase ii study of tarceva (erlotinib) and predictive markers as first-line treatment of advanced non-small cell lung cancer for patients unfit for chemotherapy (nsclc) clinical phase ii stage iiib or iv non-small cell lung cancer (nsclc) primary end point: disease control rate (= cr+pr and sd at 8 weeks /patients). secondary end point: safety (serious adverse events, adverse events leading to premature withdrawal, unexpected tarcevatm related aes) .correlation of egfr expression rate (her1) and fish potentially predictive for response. an open-label, non randomized, multicenter, clinical trial of tarcevatm as single agent the sample size is 29 patients in 2 stages and based on simon´s optimal 2 stage design. stage 1 will accrue 10 patients, if less than 1 response is observed the study will stop; if more than 1 response is observed the accrual will continue up till 29 patients. a total of 29 patients would be entered and the treatment will be declared to have sufficient activity to deserve further attention if at least 5 patients obtain disease control.


Eligibility criteria:
inclusion criteria: * histological or cytological documented diagnosis of inoperable, locally advanced, recurrent or metastatic (stage iiib or stage iv) nsclc. * chemo-naïve patients. * patients who are in the investigator's opinion not medically suitable for chemotherapy. * measurable disease according to the recist criteria. * ecog performance status of 0 - 3. * life expectancy of at least 12 weeks. * patients must be able to take oral medication. * serum calcium within normal ranges * ≥ 4 weeks since prior surgery or radiation therapy * for all females of childbearing potential a negative pregnancy test must be obtained within 48 hours before starting therapy and must use effective contraception * 18 years of age or older * written (signed) informed consent to participate in the study exclusion criteria: * prior systemic antitumor therapy * any unstable systemic disease which according to the investigator contraindicates the use of the study drug render the subject at high risk from treatment complications (including active infection, unstable angina, myocardial infarction within the previous month, inflammatory bowel disease, hepatic disease with serum bilirubin ≥ 2 upper limit of normal (uln) or ast and/or alt ≥ 2 x uln (or ≥ 5 x uln if clearly attributable to liver metastasis), renal disease with acute renal failure or serum creatinine ≥ 5 x uln. * any other malignancies within 5 years (except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer). * nursing mothers or pregnant woman. * hypersensitivity to tarceva or co-formulants. * patients with brain metastasis or spinal cord compression that has not yet been definitively treated with surgery and/or radiation. * patients with brain metastasis or spinal cord compression that not are in a stable condition despite treatment with steroids.

Keywords: egfr expression erlotinib
effects of thrust versus non-thrust thoracic manipulation on mechanical neck pain.

Conditions: Neck Pain

Summary: neck pain ranks as the 4th leading cause of disability, with high prevalence of mechanical neck pain in young population. as high as 30% of %. individuals suffering from neck often report difficulty in performance of daily life, absence from work and decreased productivity. several manual therapy treatment approaches are used for mechanical neck pain. the focus of this study is to compare the effectiveness of thrust and non-thrust thoracic manipulation for the treatment of mechanical neck pain in young population

craniovertebral angle, cervical range of motion and pain will be noted for each participant.

Eligibility criteria:
inclusion criteria * both genders * age: 18-24 years * symptoms \<30 days * fabqpa score \<12 * increased upper thoracic spine kyphosis (visual estimate) * cva \< 48 degrees exclusion criteria * symptoms distal to shoulder * aggravation of symptoms with looking up * radiating lower back pain * neurological deficit * previous surgery * spondylolisthesis * spinal stenosis * inflammatory disease * vertebrobasilar artery insufficiency * pregnancy
serum-bank for pancreatic cancer

Conditions: Adenocarcinoma

Summary: this study is about pancreatic cancer. if the diagnostic cancer is done at an early stage (\<2cm), the chances of recovery are very good. but the main problem is there is not any detections means for this cancer. sadly, when there is a cancer diagnostic , it's already too late in the majority of cases, because the cancer is in an advanced case. today, there is no any effective means of detection... blood markers can be a simple means of early detection

the purpose of this study is to establish a sero-library in a case-control cohort to assess several potentially useful serum biomarkers, such as adiponectin in the early diagnosis of pancreatic cancer.

Eligibility criteria:
adenocarcinoma group inclusion criteria: * documented adenocarcinoma (cytology / anatomopathology), all stages, except if the tumor is immediately resectable and does not require preoperative cytological evidence. in this case, the inclusion and the first collection of the sero bank is done preoperatively. the diagnostic confirmation will therefore be made post-operatively at the risk of being excluded in the event of a different diagnosis. * at the start of treatment (before surgery / 1st course of chemotherapy) * age ≥ 18 years * patient affiliated or entitled to a social security system exclusion criteria: * patient refusal * acute renal failure * child-pugh b or c cirrhosis * patient under guardianship or curators * other synchronous cancer or history of cancer \<5 years * language barrier control group inclusion criteria: * age ≥ 40 years * patient affiliated or entitled to a social security system * digestive endoscopy for any reason other than cancer or chronic inflammatory bowel disease exclusion criteria: * patient refusal * acute renal failure * child-pugh b or c cirrhosis * patient under guardianship or curators * other synchronous cancer or history of cancer \<5 years

Keywords: adenocarcinoma pancreatic cancer adiponectin blood sample
manipulation of dietary protein and the anabolic response

Conditions: Focus: Anabolic Response to Food Intake in Young Individuals; Condition Relevance: Skeletal Muscle Health, Sarcopenia

Summary: in the present study, the effect of habitual dietary protein on the anabolic response will be investigated.


Eligibility criteria:
inclusion criteria: * males * aged between 18-35 years * healthy, recreationally active * bmi \< 30 kg/m2 exclusion criteria: * smoking * allergies to milk proteins (whey or casein) * vegetarians * diagnosed gi tract diseases * female * arthritic conditions * a history of neuromuscular problems * previous participation in amino acid tracer studies * individuals on any medications known to affect protein metabolism (i.e. corticosteroids, non-steroidal anti-inflammatories, or prescription strength acne medications

Keywords: muscle protein synthesis dietary protein
assessment of long-term infliximab for psoriasis (p05319)

Conditions: Psoriasis

Summary: this is a prospective phase 4, open-label, non-randomized, observational, multi-center study of infliximab in participants with plaque-type psoriasis to assess the clinical response in real-world practice of long-term maintenance therapy with infliximab 5 mg/kg body weight in a psoriasis population, prescribed in a regimen in accordance with the product monograph (pm) for canada, the approved summary sheet of product characteristics (spc) for countries in the european union (eu), or per label according to local guidelines for all other participating countries.

this study will be conducted in two phases: the 50-week treatment period and the 48-week extended treatment period.

Eligibility criteria:
inclusion criteria: * participant must have a diagnosis of plaque-type psoriasis * participant's physician must have decided, with the subject's consent, to start treatment with infliximab * participant must demonstrate willingness to participate in the study and agree with the procedures of the study by signing the written informed consent * for inclusion into the extended treatment period, participant must have completed 50 weeks of infliximab treatment in the treatment period * for inclusion into the extended treatment period, participant must be continuing treatment with intravenous infliximab * for inclusion into the extended treatment period, participant must have an improvement in their pasi score of greater than or equal to 25% at the time of entry into to the extended treatment period exclusion criteria: for the treatment period * given the non-interventional nature of the study, no specific exclusion criteria will be applied to a participant so long as the participant is eligible for the trial (inclusion criteria). the treating physician is expected, as in normal clinical practice, to follow the pm (canada), the approved spc (eu), or local labeling (for all other participating countries) regarding contraindications and precautions for the extended treatment period * given the non-interventional nature of the study, no specific exclusion criteria will be applied to a participant so long as the participant is receiving infliximab treatment in accordance with the pm (canada), the approved spc (eu), or local labeling (for all other participating countries) regarding contraindications, precautions, dosing and frequency of administration
assessing a limited ultrasound protocol in ddh

Conditions: Developmental Dysplasia of the Hip

Summary: developmental dysplasia of the hip (ddh) is a common diagnosis in children that if untreated may lead to degeneration and arthritis of the hip joint at a young age. ultrasound imaging is used to monitor progress of the developing hip joint during treatment. initial data from our practice suggests that interim ultrasounds do not alter the course or outcome of treatment. additionally, these ultrasounds add significant time to clinic visits and carry a substantial cost to the health care system. the goal of this study is to determine if limiting the number of ultrasounds during treatment results in the same outcomes while also evaluating the amount of time and money saved by omitting the ultrasounds.


Eligibility criteria:
inclusion criteria: * aged 0-6 months at time of diagnosis * clinical and ultrasound diagnosis of stable developmental dysplasia of the hip * children with dislocated/ unstable ddh will be included once the hip becomes stable * treated with pavlik harness * assessed and treated at the sickkids baby hip clinic exclusion criteria: * underlying neuromuscular disease * teratologic hip dysplasia * prior treatment at other institutions * non-compliance with treatment protocol